Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.40 |
| ▸ | ECE1 | P42892 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 4/20 | 0.38 |
| ▸ | CPA1 | P15085 | 4/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9545901 | 0.94 | MME (0.43) | MMEECE1PTPN1L3MBTL1 | |
| SCHEMBL3705736 | 0.94 | MME (0.43) | MMEECE1PTPN1L3MBTL1 | |
| SCHEMBL3705739 | 0.94 | MME (0.43) | MMEECE1PTPN1L3MBTL1 | |
| SCHEMBL7364721 | 0.80 | PTPN1 (0.43) | MMEPTPN1ACECPA1ACE2 | |
| SCHEMBL852956 | 0.80 | PTPN1 (0.43) | MMEPTPN1ACECPA1ACE2 | |
| SCHEMBL18129829 | 0.80 | PTPN1 (0.43) | MMEPTPN1ACECPA1ACE2 | |
| SCHEMBL7367519 | 0.77 | MME (0.46) | MMEECE1PTPN1ACE | |
| SCHEMBL9847993 | 0.76 | FOLH1 (0.54) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL9847998 | 0.76 | FOLH1 (0.54) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL3506385 | 0.76 | MME (0.58) | MMEACEL3MBTL1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362868-B1 | PROCESS FOR THE PREPARATION OF PROTECTED L-ALANINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | disclosed |
| EP-0820433-B1 | O-MALONYLTYROSYL COMPOUNDS, O-MALONYLTYROSYL COMPOUND-CONTAINING PEPTIDES, AND USES THEREOF | US GOV HEALTH & HUMAN SERV (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | disclosed |
| EP-0820433-A1 | O-MALONYLTYROSYL COMPOUNDS, O-MALONYLTYROSYL COMPOUND-CONTAINING PEPTIDES, AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5688992-A | COMPOUNDS FOR TREATMENT OF SIGNALING PATHWAYS IN IMMUNE DISFUNCTION, CANCER AND DIABETES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1996030332-A1 | O-MALONYLTYROSYL COMPOUNDS, O-MALONYLTYROSYL COMPOUND-CONTAINING PEPTIDES, AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTHA ND HUMAN SERVICES (US) | 1996-10-03 | — | — | WO | disclosed |